AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min chapter
33. B-Cell Depleting Therapies and COVID-19
ACR on Air
The Effects of Dosing Retuximab on the Return of B Cells
There is a loose association between the interim length between your last dose of retuximab and then when you get vaccinated. The longer that period, the more likely you're out to generate good, humeral responses. And this largely correlates with the return of B cells. But there's data that was published maybe a couple months ago from people who were B cell depleted and had really poor responses after the second dose; they still had very poor responses. Of those that did have good responses, they tend to be further out from the last B cell depleting therapy.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode